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PAST
The routine use of sentinel lymph node biopsy (SLNB) to
accurately stage melanoma patients has been incorporated
into most international melanoma guidelines. On average,
over 80% of patients are sentinel node negative.1 However,
these patients still require follow-up, since the risk of
locoregional or distant spread, although comparatively low,
remains a possibility. Approximately 90% of recurrences
occur within 3 years of diagnosis for American Joint Com-
mittee on Cancer (AJCC) stage II melanomas, but for AJCC
stage I melanomas; a significant proportion of recurrences
occur after a substantial delay.2 Accordingly, it is chal-
lenging for national guidelines committees to devise simple
follow-up schedules for melanoma patients.
PRESENT
The melanoma follow-up (MelFO) study is an interna-
tional phase III randomized controlled trial where
participants are randomized into two groups—one
following the conventional schedule recommended in the
UK National Institutes for Health and Care Excellence
(NICE) melanoma guidelines,3 and one whose follow-up
was an AJCC stage-adjusted reduced schedule. Impor-
tantly, the primary endpoint for this study is patients’
quality of life (QoL), although secondary endpoints include
the usual standard outcomes data such as disease-specific
and overall survival. We found that both cohorts expressed
high satisfaction with their regimens ([ 93%).4 Overall
compliance with the follow-up schedules was high at the 1-
and 3-year timepoints (68.5% and 66.5%, respectively). At
3 years, no significant group effect was found on any
patient-reported outcomes measure scores, indicating no
QoL difference between the follow-up protocols. The
recurrence rate was identical (approximately 16%) and
self-examination was the main method of detection for
both groups (approximately 70%). Melanoma-specific
survival was also identical.
FUTURE
These reflections were written at a time when most
modern healthcare services have been disrupted beyond
recognition during the COVID-19 pandemic. It is likely
that many services will be rationalized in the future, once
the pandemic subsides. Accordingly, evidenced-based fol-
low-up regimens will be needed to ensure that the
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appropriate balance is struck between diagnosing early the
few recurrences in low-risk groups such as these and not
overburdening both patients and society alike.
The UK MelFO study has shown that 3 years after
staging with a negative SLNB, AJCC stage IB–IIC cuta-
neous melanoma patients assigned to the prescribed
reduced stage-adjusted follow-up schedule reported no
difference in levels of anxiety, cancer worry, and mental
health-related QoL when compared with those of patients
assigned to the follow-up schedule as currently advised in
the UK NICE melanoma guideline. These results mirror the
findings of the Dutch group who recently reported very
similar results using the same protocol in 2019.5 We
anticipate reporting the combined data for the final out-
come of the study at the end of 2020, with adequate power
to detect any difference in recurrence rates. It is our hope
that the results will assist future national guideline com-
mittees designing protocols for the follow-up of cutaneous
melanoma patients.
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